University of Kent

Kent Academic Repository

Khan, Adan, Siddiqui, Momina Riaz, Davidson, Leezza Faboro, Yip, Benjamin, Chelikani, Lisa, Faraz, Fatima, Courtnage, Lewis and Sadiq, Soban (2025) *Role of Plasma Inflammatory and Blood Biomarkers in Cerebral Small Vessel Disease*. In: Cutting-Edge Diagnostic Technologies in Cardiovascular Diseases. CRC Press, pp. 92-111.

Downloaded from
https://kar.kent.ac.uk/113595/ The University of Kent's Academic Repository KAR

The version of record is available from
https://doi.org/10.1201/9781003481621-6

This document version
Author's Accepted Manuscript

DOI for this version

Licence for this version
CC BY (Attribution)

Additional information

Versions of research works

Versions of Record
If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts
If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in ***Title of Journal*** , Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries
If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies).

Role of Plasma Inflammatory and Blood biomarkers in CSVD

Table of contents:

Author Biography

Adan Khan is a medical student at Kent Medway Medical School, focusing on the intersections of digital health, AI, and medical innovation. He has contributed to high-impact research and has published studies on advanced AI applications in healthcare. He has completed advanced AI and Machine Learning courses through prestigious institutions, including MIT, Harvard, and Stanford. Adan co-founded Diversity in Medical Academia (DIMA), where he promotes inclusivity and supports students in research and academia internationally. As a Fides Member of the WHO, he is actively involved in combatting health misinformation. He is also a peer reviewer for prominent journals, including the British Medical Journal and National Institute for Health and Care Research.
a.khan976@kmms.ac.uk

Momina Riaz Siddiqui is a medical student from Rawalpindi Medical University. Her interests in research include artificial intelligence in healthcare with a special interest in cardiology.
momina.s40403@gmail.com

Leezza Faboro Davidson is a medical student at Kent and Medway Medical School. Although this is her first publication, she also has interests in women's health and hopes to the contribute to the advancement of the understanding of menopause in the future.
l.faborodavidson450@kmms.ac.uk

Benjamin Yip is a final-year medical student with a diverse interest in research and medicine. He has completed multiple research-based certifications from Johns Hopkins University, broaden his research and analytical skills. Benjamin's previous research includes producing a systematic review evaluating rehabilitation protocols to optimize recovery in simple elbow dislocations. As a National Institute of Health Research summer intern, he also collaborated with the University of Kent and the Kyoto Institute of Technology to develop and evaluate an artificial intelligence-based platform aimed at enhancing peer support counseling. Demonstrating commitment to medical education and leadership,

Benjamin co-founded and co-led the Dermatology and Anaesthetic Society.
b.yip60@kmms.ac.uk

Lisa Chelikani is a penultimate-year medical student at Kent and Medway Medical School with a strong interest in research and has aspirations to contribute to humanitarian efforts. Her academic focus centers on surgical techniques and advancements, with a commitment to enhancing patient outcomes through both clinical practice and innovative research.
l.chelikani2@kmms.ac.uk

Fatima Faraz received her Bachelor of Medicine and Bachelor of Surgery (MBBS) from Rawalpindi Medical University, Pakistan in 2023. Her research interests include machine learning and artificial intelligence in healthcare.
fatima.faraz49@gmail.com

Lewis Courtnage is a medical student at Kent and Medway medical school with interests in surgery and medical education. He has undertaken multiple leadership roles within his medical school including Trauma and Orthopaedic society president where he works to organise teaching events within the area of Kent.
L.courtnage694@kmms.ac.uk

Soban Sadiq is Senior Lecturer and Vertical Theme Lead of Clinical Pharmacology and Therapeutics at Kent and Medway medical school with interest in Clinical Pharmacology, Medical education and drug- induced cardio-metabolic toxicities. He is also Prescribing Safety Assessment (PSA) Academic Lead for KMMS. He is also review Editor for Pharmacology Research and Perspective (British Pharmacological Society Journal).
soban.sadiq@kmms.ac.uk

Chapter 06:
Role of Plasma Inflammatory and Blood biomarkers in CSVD

Adan Khan [1,2], Momina Riaz Siddiqui [3], Leezza Faboro Davidson [4], Benjamin Yip [5], Lisa Chelikani [6], Fatima Faraz [7], Lewis Courtnage [8], Soban Sadiq [9]

Affiliations:

1. Kent and Medway Medical School, Canterbury, Kent, UK (a.khan976@kmms.ac.uk), ORCID: https://orcid.org/0000-0003-3952-113x
2. Education and Research Unit, Diversity In Medical Academia (DIMA)
3. Rawalpindi Medical University, Rawalpindi, Pakistan, (momina.s40403@gmail.com) ORCID: https://orcid.org/0009-0003-7851-4693
4. Kent and Medway Medical School, Canterbury, Kent, UK (l.faborodavidson450@kmms.ac.uk) ORCID: https://orcid.org/0009-0004-7297-4282
5. Kent and Medway Medical School, Canterbury, Kent, UK (b.yip60@kmms.ac.uk), ORCID: https://orcid.org/0009-0006-3025-5997
6. Kent and Medway Medical School, Canterbury, Kent, UK (l.chelikani2@kmms.ac.uk), ORCID: https://orcid.org/0009-0001-3030-5492
7. Department of Medicine, Rawalpindi Medical University, Pakistan (fatima.faraz49@gmail.com)
8. Kent and Medway Medical School, Canterbury, Kent, UK (l.courtnage694@kmms.ac.uk) ORCID: https://orcid.org/0009-0002-2647-6720
9. Kent and Medway Medical School, Canterbury, Kent, UK (soban.sadiq@kmms.ac.uk) ORCID: https://orcid.org/0009-0008-9016-1807

Abstract

Cerebral small vessel disease (CSVD) is a significant contributor to cognitive decline, stroke, and dementia. This review explores the role of biomarkers in CSVD, examining their potential in diagnosis, prognosis, and disease monitoring. We discuss various biomarkers related to endothelial dysfunction, inflammation, and neuroimaging features. The paper highlights the clinical implications of these biomarkers, current challenges in their application, and future directions in CSVD biomarker research. Emerging technologies, multi-marker approaches, and the potential for personalized medicine are considered. While significant progress has been made, further research is needed to fully realize the potential of biomarkers in improving CSVD management and patient outcomes.

Keywords - CSVD Biomarkers, Neuroinflammation, Personalized Medicine

6.1 Introduction

CSVD encompasses conditions affecting the brain's small blood vessels, significantly contributing to cognitive decline, stroke, and dementia, especially in ageing populations (1, 2). Despite its impact on public health, CSVD is challenging to diagnose and manage early due to its complex progression and subtle initial symptoms (3).

Recent advancements in biomarker research offer promising avenues for enhancing our understanding of CSVD pathophysiology. Biomarkers, particularly those derived from plasma and blood, provide minimally invasive methods to assess disease processes, complementing traditional neuroimaging techniques (4).

Pathological hallmarks of CSVD, such as endothelial dysfunction, blood-brain barrier disruption, and chronic inflammation, present rich opportunities for biomarker discovery (4,5). These biomarkers range from markers of endothelial damage to inflammatory mediators and indicators of neuronal injury.

This review explores the role of plasma inflammatory and blood biomarkers in CSVD, examining their potential in diagnosis, prognosis, and disease monitoring. We aim to synthesize current knowledge to provide insights into the interplay between these biomarkers and CSVD pathophysiology, which could lead to timely interventions and improved patient outcomes.

The paper is structured first to provide an overview of CSVD pathophysiology and neuroimaging markers, followed by a detailed discussion on specific biomarkers and their clinical implications. We also address challenges in biomarker research and explore future directions, including emerging biomarkers and multi-marker approaches.

Through this comprehensive review, we hope to enhance the management of CSVD, improve early diagnosis, guide therapeutic interventions, and ultimately improve patient outcomes.

6.2 Brief overview of CSVD

6.2.1 Objective of review

This review aims to provide an overview of the importance of biomarkers in CSVD research and clinical practice. The primary objectives are to review the pathophysiology of CSVD, highlighting the involvement of endothelial dysfunction, blood-brain barrier disruption, and neuroinflammation. Additionally, it will review neuroimaging markers, including white matter hyperintensities, lacunes, cerebral microbleeds, and enlarged perivascular spaces obtained from Magentic Resonance Imaging (MRI), Computed Tomography (CT) and Positron Emission Tomography (PET) scans for diagnosing and assessing the severity of CSVD.

The chapter will also review plasma inflammatory and blood biomarkers associated with CSVD, highlighting specific markers such as Intercellular Adhesion Molecule-1(ICAM), Vascular Cell Adhesion Molecule-1 (VCAM), Vascular Endothelial Growth Factor (VEGF), homocysteine, and Von Willebrand factor for endothelial dysfunction; C-reactive protein, Tumor Necrosis Factor Alpha (TNF-α), fibrinogen, and interleukins (IL-6, IL-10) for inflammation; neurofilament light chains for nerve damage; and matrix metalloproteinases for blood-brain barrier injury.

Furthermore, the application of these biomarkers will be examined, emphasizing their diagnostic potential, prognostic value, role in monitoring disease progression, and utility for identifying therapeutic targets. The chapter will also address the challenges and limitations in biomarker research for CSVD, such as variability in measurement techniques, lack of specificity, and confounding factors. Finally, future directions in biomarker research will be explored, highlighting novel biomarkers, multi-marker approaches, integration with neuroimaging, and the potential for personalized medicine.

6.3 Application and Relevance of Biomarkers

6.3.1 Imaging biomarkers

Imaging biomarkers play a crucial role in clinical research and the management of CSVD by enhancing the accuracy of diagnosis, disease monitoring, and evaluation of treatment efficacy. MRI markers such as white matter hyperintensities (WMH), cerebral microbleeds (CMB), and diffusion tensor imaging (DTI) are used to confirm CSVD in study populations, ensuring the relevance and reliability of clinical trial outcomes. These markers are handy for selecting participants with a high risk of disease progression, reducing the required sample size for clinical trials by selecting participants likely to produce measurable outcomes (6).

Furthermore, MRI techniques, including ultra-high-field, resting-state functional, and blood perfusion, may enhance cerebral and microvascular structure imaging, aiding early diagnosis and monitoring of CSVD (7). In addition, DTI helps image microstructural changes in white matter to correlate these changes with cognitive performance and disease progression (8). Moreover, PET can distinguish between vascular and degenerative cognitive impairments, providing further insights into the disease's impact (7).
In clinical trials, MRI markers serve as reliable surrogate endpoints. For instance, WMH volume, lacunae, CMB number, brain volume, and DTI parameters can be used in phase 2 trials to monitor disease progression and treatment efficacy efficiently. These markers are sensitive to change and correlate strongly with clinical outcomes, allowing for smaller, more efficient trials before progressing to more extensive phase 3 trials (8).

Finally, composite biomarker scores, such as the total CSVD score incorporating multiple imaging biomarkers, can diagnose and assess CSVD burden. Such tools can be enhanced by machine and deep learning algorithms to improve the detection rate and evaluation of CSVD (9).

6.3.2 Circulatory Biomarkers

In addition to imaging biomarkers, circulatory biomarkers have valuable applications in CSVD research and clinical practice. Blood-based biomarkers are particularly promising due to their low cost and ease of collection, making them suitable for routine diagnostic use. One such biomarker is the serum neurofilament light chain (NfL), which indicates neuroaxonal injury and correlates with MRI markers of CSVD. However, despite its potential to stratify dementia risk, further longitudinal studies are required to validate its efficacy in monitoring CSVD (6).

Besides NfL, several other markers are influential in CSVD research and management. Markers of vascular endothelial injury, such as CAM1, VEGF, and Endothelin-1 and Nitric Oxide (ET-1/NO) are associated with CSVD pathologies (10). CAM1 is linked to white matter lesions, while VEGF is associated with cognitive impairment. ET-1/NO is crucial for maintaining vascular stability and function (10).
Moreover, inflammatory markers are also relevant. C-reactive Protein (CRP) is associated with endothelial dysfunction and cognitive decline, whereas Interleukin-6 (IL-6) is linked to chronic inflammation and white matter lesions (10). Lipoprotein Phospholipase A2 (LP-PLA2) has been demonstrated to contribute to atherosclerosis and endothelial cell dysfunction, and TNF-α to exacerbate neurovascular damage and cognitive impairment.

Finally, oxidative stress markers are valuable for evaluating disease progression. Such markers include Peroxisome Proliferator-Activated Receptor (PPAR) and Paraoxonase (PON), which are associated with white matter lesions and atherosclerosis. Additional markers, including Matrix Metalloproteinases (MMPs) and albumin-to-serum albumin ratio, which quantify blood-brain barrier (BBB) integrity, are correlated with the severity of white matter lesions.

6.4 Pathophysiology of CSVD

Small vessels found throughout the body are defined by their diameter falling under 1mm, including small arteries, arterioles, small veins, venules and capillaries. Within the brain, these are each found to supply individual areas below the brain surface that experience little vascular overlap or communication - therefore, blockage of blood flow through these vessels is likely to result in infarction. Small vessels form part of the neurovascular unit, also made of other cells which work in synergy to create the blood brain barrier, maintain cerebral blood flow and ensure normal metabolic activity and therefore normal neuronal function. Damage to the neurovascular unit can cause CVSD through multiple processes (11).

Small vessel disease, a complex condition, has six subtypes based on cause, each with a unique pathophysiology. The three predominant types are listed below, each with its own set of implications for diagnosis, treatment, and patient outcomes.

6.4.1 Type 1



Figure 6.1: Type 1 CSVD Illustrated

Type 1, the commonest kind of CSVD, may be referred to as “hypertensive arteriopathy” (although hypertension is not the only risk factor for the disease), “arteriosclerosis” or “arteriolosclerosis”. It is a sporadic disease linked to risk factors such as age, hypertension and diabetes mellitus. Histopathological changes - of which any number may be present, as shown in figure 1, can be used to subtype the disease and include:

- Microatheromas (fatty plaques with a fibrous cap within the vessel intima)
- Lipohyalinosis (accumulation of lipids with a waxy appearance within the vessel wall itself)
- Fibrinoid Necrosis (death of small vessel tissue)
- Microaneurysms (dilations within small vessels)

These changes are mainly found in arterioles supplying white matter in the brain, where demyelination, small bleeds and lacunar infarcts may also be found (12).

6.4.2 Type 2

Type 2, named cerebral amyloid angiopathy, can be sporadic or hereditary and is linked with the APO epsilon4 and two alleles. It is defined by the accumulation of amyloid-beta in the walls of leptomeningeal and cortical small vessels, predominantly in small arteries and arterioles. This is likely due to an imbalance between the formation and clearance of amyloid beta. This accumulation leads to the activation of immune mediators, which leads to neurotoxic-induced destruction of vascular and parenchymal brain contents (13). It is further divided into two genetically different categories informed by the affected areas: type 1 involves the cortical capillaries, whereas, in type 2, deposits are found solely in the leptomeningeal and cortical arteries. Infiltration within the tunica media causes fibrinoid necrosis and loss of smooth cells, reducing the resilience of vessels, making them more vulnerable to damage and, therefore, microaneurysms, wall rupture and occlusion, which cause damage to the brain parenchyma. Although the endothelial cells are preserved, beta-amyloid causes dysfunction within them; the tight junction proteins connecting them are lost, which in the capillaries causes damage to the BBB (11).

6.4.3 Type 3

Type 3, named genetic small vessel disease, comprises multiple monogenic (involving a single gene) disorders and causes a small fraction of CVSD (14). Multiple forms are listed here.

CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic small vessel disease. It is caused by a mutation in NOTCH 3, a receptor found on small vessel smooth muscle cells and pericytes. This mutation leads to the accumulation of the receptor and other proteins outside

these cells (15). As a result, small penetrating cerebral and leptomeningeal arteries experience stenosis of the lumen, impairing cerebral blood flow and causing white matter myelin loss (14).

CARASIL: Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is caused by HTRA1 mutations (15). Rather than narrowing of vessels, arterial loss of smooth muscle and adventitial thickness impairs blood flow through vessel expansion and collapse.

6.4.4 Type 4 collagen mutations

Type 4 collagen—found in vessel basement membranes—is coded for in the Collagen, Type IV, Alpha 1 (COL4A1) and Collagen, Type IV, Alpha 2 (COL4A2) genes. Mutations here cause faults in basement membrane stability, which lead to small vessel disease (14).

PADMAL: Pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL) is caused by a mutation in an untranslated region of COL4A1 (different from collagen type 4 mutations), which causes its upregulation. Investigative autopsy has shown increased elastic fibres in the tunica intima and medial atrophy in arterioles and small arteries, leading to lacunar infarcts (14).

Fabry disease: Fabry disease, characterised by dysfunction in the enzyme alpha-galactosidase, has X-linked inheritance and comprises several potential mutations. Due to alpha-galactosidase dysfunction, glycosphingolipids accumulate mainly in vessels' endothelium and smooth muscle (14).

6.4.5 Endothelial dysfunction and BBB disruption

The endothelium, consisting of a single layer of endothelial cells (ECs), is the innermost layer of all blood vessels, which separates intravascular and extravascular components. It has a multifaceted role, supporting thrombotic, inflammatory and inflammatory activity and vascular tone (16). The basement membrane and tight junctions supporting ECs in the brain form a vital part of the BBB. EC dysfunction is regarded to be the earliest stage of CSVD, and may be intrinsically connected to both the cause and the result of the disease. Although EC dysfunction is joint in those with atherosclerosis or vascular risk factors, the cause for this correlation is still unknown (17).

Damage to the ECs may lead to small vessel disease through several ways of dysfunction. For example, overactivation of endothelium takes on a pathological pro-thrombotic and pro-inflammatory phenotype. Endothelial cell dysfunction leads to reduced cerebral blood flow due to its role in producing vasodilatory and vasoconstrictory mediators such as NO and endothelin; in dysfunction, primarily vasodilation is impaired. This may be due to the production of reactive oxygen species such as xanthine oxidase and NOX, reducing the production and bioavailability of NO. Overconsumption of salt may also reduce NO secretion

through increased interleukin-17 signalling. The loss of vasodilation, in combination with stiffness in larger arteries, causes an increase in small vessel blood flow, further damaging the endothelium. Endothelial dysfunction may also cause increased BBB leakage due to loss of structure in the tight junction proteins. This has several consequences, such as fibrinogen and immune cells crossing the BBB (leading to inflammation, neuronal loss and demyelination) and decreased fluid drainage through the perivascular space. Damage to the basement membrane of small vessels and deposition of leaked extracellular matrix components result in vessel wall stiffening (15).

6.5 Neuroimaging Markers of CSVD

CSVD is primarily investigated using MRI due to its greater specificity and sensitivity in identifying pathological alterations (neuroimaging markers) associated with the disease, surpassing earlier modalities like CT (18). MRI is used to identify neuroimaging markers of CSVD, including white matter hyperintensities, enlarged perivascular spaces, cerebral microbleeds, lacunar infarcts and brain atrophy (19). The Standards for Reporting Vascular Changes on Neuroimaging-2 (STRIVE-2) offer valuable guidance. STRIVE-2 guidelines aim to standardise terminology related to neuroimaging markers, enhance the consistency and clarity of neuroimaging reports and provide a framework for researchers reporting on CSVD (20).

6.5.1 White Matter Hyperintensities

White matter hyperintensities of presumed vascular origin, the most typical manifestations of CSVD, are regions in the brain's white matter that appear hyperintense on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) MRI while appearing hypointense on T1-weighted MRI and are generally symmetrical in both hemispheres (21, 22). The pathogenesis of WMHs due to CSVD is complex. It involves various factors, including cerebrovascular dysfunction, impaired cerebrovascular reactivity and increased vascular pulsatility, blood-brain barrier dysfunction, venous collagenosis, reduced cerebral blood flow, and neuroinflammation (22). WMHs are primarily divided into two groups anatomically: deep and periventricular white matter regions and can be graded using the Fazekas scale, which divides the WMHs based on confluence and size (23, 24). The incidence of WMHs increases to over 90% in older age, and risk factors are thought to be ageing, hypertension, smoking and diabetes (25, 26, 27). The presence of WMHs is thought to predispose the individual to a higher occurrence of stroke, gait and balance dysfunctions, dementia and mood disorders and finally, cognitive impairment (20, 28).

6.5.2 Enlarged perivascular spaces

Perivascular spaces are fluid-filled cavities surrounding blood vessels in the brain, best visualised using T2-weighted MRI sequences (29, 30). They are thought to result from a heterogeneous process involving chronic inflammation leading to blood-brain barrier dysfunction, reduced cerebral blood flow and hypoxia, pericyte degeneration, and impaired fluid clearance, ultimately contributing to neurovascular dysfunction (31). Various classification systems exist for perivascular spaces, the latest being the Edinburgh Perivascular Spaces Scale (EPVS). The EPVS is a modified version of the previously widely

used version of the scale. The EPVS assesses the severity of enlarged perivascular spaces in critical regions, including the basal ganglia, centrum semiovale, and midbrain, which are considered optimal for visualising perivascular spaces (32). Enlarged perivascular spaces are associated with risk factors such as ageing, hypertension, smoking, and diabetes (33). Severe perivascular space pathology is associated with a decline in cognitive function, dementia, and increased stroke risk (34, 31).

6.5.3 Cerebral Microbleeds

Cerebral microbleeds are small, chronic brain haemorrhages of hemosiderin, a product of blood degradation, found within macrophages near abnormal blood vessels (35). These microbleeds are best visualised on T2-weighted MRI and susceptibility-weighted MRI sequences as hypodense foci (36). The pathophysiology behind cerebral microbleeds is primarily linked to cerebral amyloid angiopathy and arteriosclerosis, which lead to structural changes in blood vessels, weakening them and causing blood-brain barrier dysfunction (20). Cerebral microbleeds are generally classified based on their location within the brain using tools such as the Brain Observer MicroBleed Scale (BOMBS) (37). Risk factors associated with cerebral microbleeds include advancing age, hypertension, cardiovascular disease, medications such as statins and antithrombotics, and the presence of the Apolipoprotein (APOE) e4 allele (38). Cerebral microbleeds have many consequences, including an increased risk of stroke, dementia (including Alzheimer's disease), and cognitive decline (39, 40).

6.5.4 **Lacunar Infarcts**

Lacunar infarcts are ischemic strokes resulting from obstructing small penetrating arteries (41). On MRI, lacunar infarcts appear hyperintense on T2-weighted and FLAIR sequences and hypointense on T1-weighted sequences (42). Symptomatic lacunar infarcts are classified into five primary syndromes: pure motor stroke, pure sensory stroke, sensorimotor stroke, dysarthria-clumsy hand syndrome, and ataxic hemiparesis (43). Several risk factors are associated with lacunar infarcts, including hypertension, smoking, diabetes mellitus, hyperlipidemia, carotid artery atherosclerosis, a history of transient ischemic attacks, and genetic factors such as CADASIL and the APOE e4 gene (44). Similar to other neuroimaging markers, lacunar infarcts are thought to be linked to cognitive impairment and vascular dementia.

6.5.5 Brain Atrophy

Brain atrophy, a reduction in brain volume unrelated to infarction or trauma, is a non-specific marker of CSVD, as it can also result from other neurodegenerative conditions (20). It is considered a late-stage manifestation of CSVD, resulting from chronic hypoperfusion and subsequent tissue damage, and often appears alongside other neuroimaging markers previously discussed (45). Increased brain atrophy is associated with more significant cognitive impairment, functional impairment, emotional and behavioural changes, and an increased risk of other health issues.

6.6 Plasma Inflammatory and Blood Biomarkers in CSVD

Endothelial dysfunction and blood-brain barrier leakage are crucial pathophysiological mechanisms that facilitate the identification of CSVD through circulating neuroinflammatory

markers. There are two distinct types of inflammation associated with the subtypes of CSVD: vascular inflammation, which is involved in CSVD characterized by deep perforator arteriopathy (DPA), and systemic inflammation, which is typically associated with cerebral amyloid angiopathy-related vascular damage (4, 13, 46).

6.6.1 Endothelial Dysfunction Markers

Blood-brain barrier and endothelial dysfunction are crucial aspects of DPA. DPA is characterized by damaged endothelial tight junctions and the deposition of leaked proteins in the surrounding small vessel walls. Endothelial-derived adhesion molecules and chemokines that recruit leucocytes are reportedly expressed at increased levels, leading to BBB disruption. This process is intricately connected to the pathological mechanism of white matter lesions (47). An increase in blood metabolites reflects the reduced endothelial and BBB function in CSVD (5).

6.6.2 ICAM and VCAM

A hallmark of white matter lesions is the increased expression of hypoxia-related and endothelial markers, particularly ICAM and VCAM. These circulating biomarkers are adhesion molecules belonging to the immunoglobulin (Ig) superfamily. They reflect endothelial injury and activation, allowing researchers to assess endothelial function (48).

ICAM-1 facilitates the adhesion of leukocytes to the endothelium and microvascular occlusion (49). In cerebral white matter lesions, endothelial cell function and BBB integrity are significantly compromised. Moreover, ICAM-1s levels are notably elevated in the affected portions of white matter. ICAM levels can serve as an independent predictor of white matter hyperintensity progression. Additionally, patients with lacunar infarcts have been observed to present with higher levels of ICAM-1 (50).

VCAM-1, a cell surface protein, plays a crucial role in the progression of atherosclerosis and endothelial dysfunction. It shows a significant association with white matter hyperintensities in the aging population (51). Higher expression of VCAM-1 is linked to endothelial activation and WMH found in CSVD (4, 50).

6.6.4 VEGF

Vascular Endothelial Growth Factor (VEGF) is a growth factor involved in angiogenesis. During this process, endothelial cells migrate towards VEGF in the hypoxic or ischemic conditions characteristic of CSVD (50). Studies indicate that VEGF is involved in vascular inflammation in cerebral microbleeds of stroke patients with CSVD, although no association has been found with WMH (52). Furthermore, VEGF plays a role in the cognitive impairments observed in CSVD (7).

6.4.4 Homocysteine

The majority of studies have found an association between Homocysteine (HCY) levels and WMH, either as a causal factor or secondary to CSVD (48). HCY is known to damage brain small vessels through various mechanisms, including inflammation, atherosclerotic plaque

formation, and endothelial dysfunction. Elevated HCY levels can impair normal endothelial cell function, potentially indicating both the formation and progression of CSVD (53).

6.6.5 Von Willebrand

Von Willebrand Factor (VWF) is a substance that mediates platelet aggregation and adhesion, serving as a marker of endothelial dysfunction. Secreted by damaged endothelial cells, VWF induces vessel damage, promotes BBB breakdown, and reduces white matter integrity. Numerous studies suggest that increased levels of VWF reflect endothelial injury (54, 55). Associations have been reported between high VWF levels and silent lacunar cerebral infarcts, periventricular hyperintensity, WMH, and deep medullary veins (21, 56).

6.6.6 Inflammatory Markers

The immune inflammatory response affects multiple pathological mechanisms of CSVD, notably vascular endothelial cell dysfunction and BBB destruction. Key inflammatory factors that can be detected include C-reactive protein (CRP), IL-6, IL-10, TNF-α, and fibrinogen. Ischemia and hypoxia are the primary risk factors that can trigger the overexpression and release of these inflammatory factors. Their accumulation can cause damage and degradation, leading to increased permeability of the BBB (7).

CRP is a sensitive, non-specific systemic marker of inflammation. This acute-phase protein is regulated by pro-inflammatory cytokines such as IL-6, IL-1, and TNF-alpha (57). Elevated CRP levels are associated with larger white matter hyperintensity volume, prevalent and incident lacunar infarcts, and deep cerebral microbleeds. There is also a significant association between plasma CRP levels and WMH and brain infarcts in the elderly, particularly in White populations (58).
Elevated CRP levels can serve as a marker for vessel occlusion, altered cerebral autoregulation, and increased vascular permeability. Plasma CRP plays a role in endothelial dysfunction through multiple mechanisms: decreasing endothelial nitric oxide synthase (eNOS) expression and bioactivity, reducing nitric oxide (NO) production, and increasing the release of vasoconstrictors and adhesion molecules such as ICAM-1, VCAM-1, and E-selectin. Thus, CRP is actively involved in endothelial activation and contributes to both small and large vessel disease progression (59,60). However, it's worth noting that one study did not find an association between CRP and small vessel disease, suggesting that CRP may not be a reliable marker in the very early stages of CSVD (61).

TNF-α is a cytokine secreted by macrophages and microglia. It results in increased permeability of the BBB, exacerbating neuroinflammation. Continuous neurovascular inflammation driven by TNF-α signaling and BBB destruction leads to neuronal damage and increases the occurrence of cognitive dysfunction in CSVD. In the context of CSVD, high levels of the TNFR2 receptor promote the pathogenesis of CMBs (49).

Fibrinogen is involved in the pathogenesis of BBB leakage and chronic ischemia of white matter, which explains the increased levels of plasma fibrinogen found in CSVD patients (62, 63). Elevated fibrinogen levels can lead to vascular endothelial damage and neurovascular damage, further aggravating CSVD. These increased levels result in higher plasma viscosity, erythrocyte aggregation, and disruptions of the endothelial cell layer integrity, thus causing vascular dysfunction (49).

Interestingly, while high fibrinogen levels are present in sporadic CSVD, they also appear in CADASIL, a genetic paradigm of CSVD. In CADASIL, high fibrinogen levels serve as an independent risk factor connected to the severity of WMHs present (62).

6.6.7 Nerve Damage Markers

Research has demonstrated that Neurofilament light chain levels in cerebrospinal fluid (CSF) increase in parallel with WMH severity. While Neurofilament Light Chain (NfL) is primarily a biomarker for determining damage to nerve axons, it has also emerged as a potential blood biomarker for active CSVD load.

Elevated levels of NfL are associated with clinically silent, ischemic CSVD-related lesions and serve as a sensitive marker of tissue damage. This biomarker offers several valuable applications in CSVD management:

1. Disease activity monitoring: NfL levels can be used to track the progression of CSVD over time.
2. Patient identification: It can help identify individuals affected by CSVD, even in the absence of overt clinical symptoms.
3. Disease severity assessment: NfL levels can reflect the severity of CSVD, providing clinicians with a quantitative measure of disease impact.

The utility of NfL as a biomarker in CSVD underscores its potential in both research and clinical settings. Its ability to detect subclinical tissue damage and correlate with disease severity makes it a promising tool for early diagnosis and monitoring of CSVD progression (49, 64).

6.6.8 Blood-Brain Barrier Injury Markers

Matrix metalloproteinases (MMPs) serve as crucial markers of blood-brain barrier injury and play a significant role in the neuroinflammatory response associated with CSVD. Of particular interest are MMP-3 and MMP-9, whose levels are notably elevated in the cerebrospinal fluid of CSVD patients (49).

Plasma MMP-9, in particular, has emerged as a valuable tool for assessing CSVD severity. Its utility stems from its correlation with the volume of white matter lesions (WML), a key indicator of CSVD progression. This relationship allows clinicians and researchers to use MMP-9 levels as a quantitative measure of disease severity.

The mechanism by which MMPs contribute to CSVD pathology is multifaceted. MMPs are primarily involved in the decomposition of basement membrane proteins, which are crucial for maintaining BBB integrity. The degradation of these proteins compromises the BBB's structural integrity, allowing MMPs to enter the CSF. Once in the CSF, MMPs can cause white matter demyelination, further exacerbating CSVD symptoms and progression.

This cascade of events highlights the central role of MMPs in CSVD pathophysiology, from initial BBB damage to subsequent white matter injury (5, 7). The ability to detect and measure MMP levels, particularly MMP-9, in plasma provides a valuable, minimally invasive method for monitoring CSVD progression and severity. This approach offers potential benefits for both clinical management and research endeavors in the field of CSVD.

6.7 Clinical Implications of Biomarkers in CSVD

Whilst current MRI imaging can identify pathology related to CSVD, they often only detect structural changes after irreversible damage has already been done to the brain (65). This means that there is a need for biomarkers that can more effectively identify early disease and possible therapeutic targets.

HCY and Asymmetric dimethylarginine (ADMA) seem to be useful in the diagnosis of CSVD (3). Homocysteine is known to be an independent risk factor for CSVD as well as being correlated with WMHs, whilst high asymmetric dimethylarginine (ADMA) levels are associated with Leukoaraiosis (damage to the white matter) and could be linked to silent cerebral infarction. Although there is no current widely used blood panel for the diagnosis of CSVD, it is possible that with further research this could become a reality (66). Biomarkers can also be used to diagnose genetic variants of CSVD (3). Testing for the NOTCH-3 receptor mutation can be used in the diagnosis of CADASIL as mentioned previously and the same follows for the HTRA1 mutation in CARASIL.

Another potential application of blood biomarkers is as prognostic indicators. For example IL-6 can be used to predict the formation of new lacunar infarcts and IL-1alpha as an indicator of high long term risk of infarction or death.

Understanding the pathways involved in the pathophysiology of CSVD is essential in identifying molecules useful for diagnosis and prognosis, but it might also lead to the discovery of new therapeutic targets, and the potential for a more individualized approach to treatment. (66).

6.8 Challenges and Limitations in Biomarker Research for CSVD

While biomarkers hold significant promise for advancing our understanding and management of CSVD, several challenges and limitations persist in this field of research:

6.8.1 Heterogeneity of CSVD

CSVD encompasses a spectrum of pathological processes affecting small blood vessels in the brain. This heterogeneity poses a significant challenge in identifying universally applicable biomarkers. Different CSVD subtypes, such as arteriolosclerosis and cerebral amyloid angiopathy, may have distinct underlying mechanisms and, consequently, different biomarker profiles (2). This diversity complicates the development of a unified biomarker panel for CSVD.

6.8.2 Lack of Specificity

Many biomarkers associated with CSVD, particularly inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6), are not specific to cerebrovascular pathology. These markers can be elevated in various systemic conditions, making it challenging to distinguish CSVD-related changes from other inflammatory processes (49). This lack of specificity can lead to false positives and complicates the interpretation of biomarker data in clinical settings.

6.8.3 Variability in Measurement Techniques

The quantification of biomarkers can vary significantly depending on the measurement techniques and assays used. This variability makes establishing standardized cut-off values and comparing results across different studies difficult. For instance, the measurement of neurofilament light chain levels, a promising marker of axonal damage in CSVD, can vary based on the assay platform used (64). Standardization of measurement techniques is crucial for the reliable application of biomarkers in clinical practice.

6.8.4 Temporal Dynamics of Biomarkers

Many biomarkers' levels can fluctuate over time and may not consistently reflect the underlying disease process. For example, acute inflammatory responses following a small subcortical infarct may temporarily elevate specific biomarkers, but these levels may not accurately represent the chronic nature of CSVD (2). Understanding the temporal dynamics of biomarkers of CSVD progression remains a significant challenge.

6.8.5 Confounding Factors

Numerous factors can influence biomarker levels, including age, comorbidities, medications, and lifestyle factors. These confounding variables can mask or exaggerate the relationship between biomarkers and CSVD. For instance, hypertension and diabetes, common comorbidities in CSVD patients, can independently affect levels of endothelial dysfunction markers (48). Controlling these confounding factors in research studies and clinical applications presents a considerable challenge.

6.8.6 Limited Longitudinal Data

Most biomarker studies in CSVD are cross-sectional, providing a snapshot of the disease at a single time. There is a need for longitudinal studies that track biomarker changes over time in CSVD progression. This limitation hinders our understanding of how biomarkers evolve throughout the disease course and their predictive value for long-term outcomes (3).

6.8.7 Translation to Clinical Practice

Despite promising research findings, translating biomarker discoveries into clinical practice remains challenging. Many biomarkers require specialized laboratory techniques or equipment that may need to be more readily available in routine clinical settings. Additionally, the cost-effectiveness of biomarker testing in CSVD management needs to be established to justify its integration into standard care protocols (6).

6.8.8 Ethical Considerations

The use of biomarkers for predicting CSVD progression or risk stratification raises ethical concerns, mainly when effective preventive or therapeutic interventions are limited. The potential psychological impact of biomarker testing on patients and the implications for insurance and employment need careful consideration (67).

Addressing these challenges requires collaborative efforts across disciplines, including neurology, biochemistry, and biostatistics. Future research should focus on large-scale, longitudinal studies with standardized biomarker measurements and comprehensive clinical and imaging data. Additionally, developing CSVD-specific biomarker panels and their validation in diverse populations will be crucial for overcoming these limitations and realizing the full potential of biomarkers in CSVD management.

6.9 Future Directions

The field of biomarker research in CSVD is rapidly evolving, with several promising avenues for future investigation and clinical application. This section explores emerging trends and potential developments that may shape the CSVD diagnosis, prognosis, and treatment landscape in the coming years.

6.9.1 Emerging Biomarkers

Recent advancements in molecular biology and neuroimaging have unveiled novel biomarkers with potential utility in CSVD:

1. MicroRNAs (miRNAs): These small, non-coding RNA molecules play crucial roles in gene regulation and have shown promise as biomarkers in various neurological conditions (68). Specific miRNA profiles associated with CSVD pathology are being investigated, potentially offering insights into disease mechanisms and progression.
2. Exosomes: These extracellular vesicles contain proteins, lipids, and nucleic acids that reflect the state of their cells of origin. Exosome-derived biomarkers from blood or cerebrospinal fluid may provide a "liquid biopsy" of brain health, offering a minimally invasive way to monitor CSVD progression (69).
3. Gut microbiome markers: Emerging evidence suggests a link between gut microbiota composition and neurological disorders (70). Future research may reveal specific microbial signatures associated with CSVD, opening new avenues for diagnosis and therapeutic interventions.

6.9.2 Multi-marker Approaches

Given the complex and multifaceted nature of CSVD, single biomarkers may not capture the full spectrum of disease processes. Multi-marker approaches hold promise for improving diagnostic accuracy and prognostic value:

1. Biomarker panels: Combining multiple biomarkers that reflect different aspects of CSVD pathology (e.g., endothelial dysfunction, inflammation, and axonal damage) may provide a more comprehensive assessment of disease status and progression (3).
2. Machine learning algorithms: Advanced computational methods can integrate data from multiple biomarkers, clinical parameters, and imaging findings to develop more accurate predictive models for CSVD outcomes (71).
3. Longitudinal profiling: Tracking changes in multiple biomarkers over time may offer insights into disease trajectory and treatment response, enabling more personalized management strategies (72)

6.9.3 Integration with Neuroimaging

The synergy between biomarkers and advanced neuroimaging techniques presents exciting opportunities for CSVD research and clinical practice:

1. Radiomics: This emerging field combines advanced image analysis with machine learning to extract quantitative features from neuroimaging data. Integrating radiomic features with blood-based biomarkers may enhance CSVD characterization and risk stratification (73).
2. PET-MRI fusion: Combining PET tomography with MRI allows simultaneous assessment of structural changes and molecular processes. Future developments may enable targeted imaging of specific CSVD biomarkers, providing unprecedented insights into disease mechanisms (74).
3. Artificial intelligence-assisted image analysis: AI algorithms can detect subtle changes in brain structure and function that may not be apparent to the human eye. Correlating these AI-derived imaging biomarkers with blood-based markers could improve early detection and monitoring of CSVD (75).

6.9.4 Potential for Personalized Medicine

The ultimate goal of biomarker research in CSVD is to enable personalized approaches to patient care:

1. Risk stratification: Refined biomarker profiles may allow clinicians to identify patients at the highest risk for CSVD progression or complications, enabling targeted preventive interventions (76).
2. Treatment selection: Biomarker-guided treatment algorithms could help clinicians choose the most appropriate therapies for individual patients based on their specific disease mechanisms and risk factors (77).
3. Monitoring treatment response: Regular biomarker assessments may provide early indications of treatment efficacy, allowing for timely adjustments to management strategies (3).
4. Drug development: Biomarkers may serve as surrogate endpoints in clinical trials, accelerating the development of new therapies for CSVD (77).

As emerging biomarkers are validated, multi-marker approaches are refined, and integration with neuroimaging techniques progresses, we move closer to the goal of personalized medicine for CSVD patients. However, realizing this potential will require continued collaborative efforts across disciplines, large-scale longitudinal studies, and careful translation of research findings into clinical practice.

6.10 Conclusion

This chapter has explored the current landscape of biomarker research in CSVD, a significant contributor to cognitive decline, stroke, and dementia. We have examined CSVD pathophysiology, focusing on endothelial dysfunction, blood-brain barrier disruption, and neuroinflammation as crucial mechanisms underlying various biomarkers.

The paper has covered a range of biomarkers, including endothelial dysfunction markers, inflammatory indicators, and neuroimaging features. These biomarkers offer the potential for improved diagnosis, prognosis, and monitoring of CSVD progression and treatment response. However, challenges such as lack of specificity and measurement variability persist.

Looking ahead, emerging biomarkers, multi-marker approaches, and integration with advanced neuroimaging techniques present promising avenues for research. The ultimate goal is to inspire a new era of healthcare with personalized medicine in CSVD management, including individualized risk assessment and treatment strategies.
While significant progress has been made, realizing the full potential of CSVD biomarkers will require continued research, large-scale studies, and careful translation into clinical practice. As our understanding grows and technologies advance, biomarker research holds great promise for improving outcomes in CSVD patients.

References:

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701.
2. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-96.
3. Peng X, Zhao J, Liu J, Li S. Advances in biomarkers of cerebral small vessel disease. Journal of Neurorestoratology. 2019;7(4):171-83.
4. Li T, Huang Y, Cai W, Chen X, Men X, Lu T, et al. Age-related cerebral small vessel disease and inflammaging. Cell Death & Disease. 2020;11(10):932.
5. Liu X, Sun P, Yang J, Fan Y. Biomarkers involved in the pathogenesis of cerebral small-vessel disease. Frontiers in Neurology. 2022;13.
6. Markus HS, van Der Flier WM, Smith EE, Bath P, Biessels GJ, Briceno E, et al. Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE): A Review. JAMA Neurology. 2022;79(11):1187-98.
7. Ren B, Tan L, Song Y, Li D, Xue B, Lai X, et al. Cerebral Small Vessel Disease: Neuroimaging Features, Biochemical Markers, Influencing Factors, Pathological Mechanism and Treatment. Frontiers in Neurology. 2022;13.
8. Benjamin P, Zeestraten E, Lambert C, Chis Ster I, Williams OA, Lawrence AJ, et al. Progression of MRI markers in cerebral small vessel disease: Sample size considerations for clinical trials. Journal of Cerebral Blood Flow & Metabolism. 2016;36(1):228-40.
9. Cuadrado-Godia E, Dwivedi P, Sharma S, Ois Santiago A, Roquer Gonzalez J, Balcells M, et al. Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke. 2018;20(3):302-20.
10. Markus HS, de Leeuw FE. Cerebral small vessel disease: Recent advances and future directions. International Journal of Stroke. 2023;18(1):4-14.
11. Singh A, Bonnell G, De Prey J, Buchwald N, Eskander K, Kincaid KJ, et al. Small-vessel disease in the brain. American Heart Journal Plus: Cardiology Research and Practice. 2023;27:100277.
12. Hannawi Y. Cerebral Small Vessel Disease: a Review of the Pathophysiological Mechanisms. Translational Stroke Research. 2024;15(6):1050-69.
13. Low A, Mak E, Rowe JB, Markus HS, O'Brien JT. Inflammation and cerebral small vessel disease: A systematic review. Ageing Research Reviews. 2019;53:100916.
14. Søndergaard CB, Nielsen JE, Hansen CK, Christensen H. Hereditary cerebral small vessel disease and stroke. Clinical Neurology and Neurosurgery. 2017;155:45-57.
15. Dupré N, Drieu A, Joutel A. Pathophysiology of cerebral small vessel disease: a journey through recent discoveries. The Journal of Clinical Investigation. 2024;134(10).
16. Krüger-Genge A, Blocki A, Franke R-P, Jung F. Vascular Endothelial Cell Biology: An Update. International Journal of Molecular Sciences. 2019;20(18):4411.

17. Maiuolo J, Muscoli C, Gliozzi M, Musolino V, Carresi C, Paone S, et al. Endothelial Dysfunction and Extra-Articular Neurological Manifestations in Rheumatoid Arthritis. Biomolecules. 2021;11(1):81.
18. Heiss W-D. The Additional Value of PET in the Assessment of Cerebral Small Vessel Disease. Journal of Nuclear Medicine. 2018;59(11):1660-4.
19. Elmståhl S, Ellström K, Siennicki-Lantz A, Lätt J, Månsson S, Månsson T, et al. Incidence of cerebral small vessel disease-related MR markers in the Swedish general population 'Good Aging in Skåne'(GÅS) study. Journal of Neurology. 2024;271(9):5997-6003.
20. Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw F-E, et al. Neuroimaging standards for research into small vessel disease 2014;advances since 2013. The Lancet Neurology. 2023;22(7):602-18.
21. Wang T, Jin A, Fu Y, Zhang Z, Li S, Wang D, et al. Heterogeneity of White Matter Hyperintensities in Cognitively Impaired Patients With Cerebral Small Vessel Disease. Frontiers in Immunology. 2021;12.
22. Li Q, Yang Y, Reis C, Tao T, Li W, Li X, et al. Cerebral Small Vessel Disease. Cell Transplantation. 2018;27(12):1711-22.
23. Lin J, Wang D, Lan L, Fan Y. Multiple Factors Involved in the Pathogenesis of White Matter Lesions. BioMed Research International. 2017;2017(1):9372050.
24. Griffanti L, Jenkinson M, Suri S, Zsoldos E, Mahmood A, Filippini N, et al. Classification and characterization of periventricular and deep white matter hyperintensities on MRI: A study in older adults. NeuroImage. 2018;170:174-81.
25. Cedres N, Ferreira D, Machado A, Shams S, Sacuiu S, Waern M, et al. Predicting Fazekas scores from automatic segmentations of white matter signal abnormalities. Aging (Albany NY). 2020;12(1):894-901.
26. Brown R, Low A, Markus HS. Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design. Journal of Neurology, Neurosurgery & Psychiatry. 2021;92(12):1271-7.
27. Gray JC, Thompson M, Bachman C, Owens MM, Murphy M, Palmer R. Associations of cigarette smoking with gray and white matter in the UK Biobank. Neuropsychopharmacology. 2020;45(7):1215-22.
28. Sun W, Huang S, Yang X, Luo Y, Liu L, Wu D. Association of ADAMTS13 activity with cerebral deep medullary vein: A community-based cross-sectional study. Heliyon. 2024;10(8):e29534.
29. Sharma R, Sekhon S, Lui F, Cascella M. White Matter Lesions. StatPearls. Treasure Island (FL) ineligible companies. 2024.
30. Rudie JD, Rauschecker AM, Nabavizadeh SA, Mohan S. Neuroimaging of Dilated Perivascular Spaces: From Benign and Pathologic Causes to Mimics. Journal of Neuroimaging. 2018;28(2):139-49.
31. Barisano G, Law M, Custer RM, Toga AW, Sepehrband F. Perivascular Space Imaging at Ultrahigh Field MR Imaging. Magnetic Resonance Imaging Clinics of North America. 2021;29(1):67-75.
32. Brown R, Benveniste H, Black SE, Charpak S, Dichgans M, Joutel A, et al. Understanding the role of the perivascular space in cerebral small vessel disease. Cardiovascular Research. 2018;114(11):1462-73.
33. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral Perivascular Spaces Visible on Magnetic Resonance Imaging: Development of a Qualitative Rating Scale and its Observer Reliability. Cerebrovascular Diseases. 2015;39(3-4):224-31.

34. Lara FR, Scruton AL, Pinheiro A, Demissie S, Parva P, Charidimou A, et al. Aging, prevalence and risk factors of MRI-visible enlarged perivascular spaces. Aging (Albany NY). 2022;14(17):6844-58.
35. Romero JR, Pinheiro A, Aparicio HJ, DeCarli CS, Demissie S, Seshadri S. MRI-Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study. Neurology. 2022;99(23):e2561-e71.
36. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimer's Research & Therapy. 2014;6(3):33.
37. Puy L, Pasi M, Rodrigues M, van Veluw SJ, Tsivgoulis G, Shoamanesh A, et al. Cerebral microbleeds: from depiction to interpretation. Journal of Neurology, Neurosurgery & Psychiatry. 2021;92(6):598-607.
38. Lee J, Sohn EH, Oh E, Lee AY. Characteristics of Cerebral Microbleeds. Dement Neurocogn Disord. 2018;17(3):73-82.
39. Kargiotis O, Safouris A, Magoufis G, Papageorgiou E, Fili M, Psychogios K, et al. Cerebral Microbleeds: Incidence, Imaging Characteristics, Common and Uncommon Causes. J Neurosonol Neuroimag. 2018;10(2):80-94.
40. Hussein AS, Shawqi M, Bahbah EI, Ragab B, Sunoqrot M, Gadallah A, et al. Do cerebral microbleeds increase the risk of dementia? A systematic review and meta-analysis. IBRO Neuroscience Reports. 2023;14:86-94.
41. Yaghi S, Raz E, Yang D, Cutting S, Mac Grory B, Elkind MS, et al. Lacunar stroke: mechanisms and therapeutic implications. Journal of Neurology, Neurosurgery & Psychiatry. 2021;92(8):823-30.
42. Das AS, Regenhardt RW, Feske SK, Gurol ME. Treatment Approaches to Lacunar Stroke. Journal of Stroke and Cerebrovascular Diseases. 2019;28(8):2055-78.
43. Barow E, Pinnschmidt H, Boutitie F, Königsberg A, Ebinger M, Endres M, et al. Symptoms and probabilistic anatomical mapping of lacunar infarcts. Neurological Research and Practice. 2020;2(1):21.
44. Gore M, Bansal K, Khan Suheb MZ, Lui F, Asuncion RMD. Lacunar Stroke. StatPearls. Treasure Island (FL) ineligible companies. 2024.
45. De Guio F, Duering M, Fazekas F, De Leeuw F-E, Greenberg SM, Pantoni L, et al. Brain atrophy in cerebral small vessel diseases: Extent, consequences, technical limitations and perspectives: The HARNESS initiative. Journal of Cerebral Blood Flow & Metabolism. 2020;40(2):231-45.
46. Boche D, Nicoll JAR. Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology. 2020;46(7):623-40.
47. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, et al. Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study. Stroke. 2008;39(7):1952-9.
48. Poggesi A, Pasi M, Pescini F, Pantoni L, Inzitari D. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review. Journal of Cerebral Blood Flow & Metabolism. 2016;36(1):72-94.
49. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology. 2015;84(8):825-32.
50. Bai T, Yu S, Feng J. Advances in the Role of Endothelial Cells in Cerebral Small Vessel Disease. Frontiers in Neurology. 2022;13.
51. Zhang D-D, Cao Y, Mu J-Y, Liu Y-M, Gao F, Han F, et al. Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study. Stroke and Vascular Neurology. 2022;7(4):302-9.

52. Zhang JB, Li MF, Zhang HX, Li ZG, Sun HR, Zhang JS, et al. Association of serum vascular endothelial growth factor levels and cerebral microbleeds in patients with Alzheimer's disease. Eur J Neurol. 2016;23(8):1337-42.
53. Li S, Li G, Luo X, Huang Y, Wen L, Li J. Endothelial Dysfunction and Hyperhomocysteinemia-Linked Cerebral Small Vessel Disease: Underlying Mechanisms and Treatment Timing. Front Neurol. 2021;12:736309.
54. Gao Y, Li D, Lin J, Thomas AM, Miao J, Chen D, et al. Cerebral small vessel disease: Pathological mechanisms and potential therapeutic targets. Front Aging Neurosci. 2022;14:961661.
55. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34(2):255-65.
56. Sun W, Huang S, Yang X, Luo Y, Liu L, Wu D. Association of ADAMTS13 activity with cerebral deep medullary vein: A community-based cross-sectional study. Heliyon. 2024;10(8):e29534.
57. Wan S, Dandu C, Han G, Guo Y, Ding Y, Song H, et al. Plasma inflammatory biomarkers in cerebral small vessel disease: A review. CNS Neuroscience & Therapeutics. 2023;29(2):498-515.
58. Hilal S, Ikram MA, Verbeek MM, Franco OH, Stoops E, Vanderstichele H, et al. C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers. Stroke. 2018;49(11):2692-8.
59. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112(6):900-5.
60. Hoshi T, Kitagawa K, Yamagami H, Furukado S, Hougaku H, Hori M. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke. 2005;36(4):768-72
61. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Niederkorn K, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke. 2006;37(12):2910-6.
62. Guo X, Deng B, Zhong L, Xie F, Qiu Q, Wei X, et al. Fibrinogen is an Independent Risk Factor for White Matter Hyperintensities in CADASIL but not in Sporadic Cerebral Small Vessel Disease Patients. Aging Dis. 2021;12(3):801-11.
63. Xu M, Li J, Xu B, Zheng Q, Sun W. Association of coagulation markers with the severity of white matter hyperintensities in cerebral small vessel disease. Front Neurol. 2024;15:1331733.
64. Gattringer, T, Pinter, D, Enzinger, C, Seifert-Held, T, Kneihsl, M., Fandler, S., et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017;89(20):2108-2114.
65. Wu L-Y, Chai YL, Cheah IK, Chia RSL, Hilal S, Arumugam TV, et al. Blood-based biomarkers of cerebral small vessel disease. Ageing Research Reviews. 2024;95:102247.
66. Vilar-Bergua A, Riba-Llena I, Nafría C, Bustamante A, Llombart V, Delgado P, et al. Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability. Journal of Cerebral Blood Flow & Metabolism. 2016;36(1):55-71.
67. Juengst E, McGowan ML, Fishman JR, Settersten Jr. RA. From “Personalized” to “Precision” Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Center Report. 2016;46(5):21-33.
68. Liang Z, Zhao Y, Ruan L, Zhu L, Jin K, Zhuge Q, et al. Impact of aging immune system on neurodegeneration and potential immunotherapies. Progress in Neurobiology. 2017;157:2-28.

69. Kanninen, KM., Bister, N, Koistinaho, J, Malm, T. Exosomes as new diagnostic tools in CNS diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2016;1862(3):403-410.
70. Sochocka M, Donskow-Lysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease-a Critical Review. Mol Neurobiol. 2019;56(3):1841-51.
71. Soun JE, Chow DS, Nagamine M, Takhtawala RS, Filippi CG, Yu W, et al. Artificial Intelligence and Acute Stroke Imaging. American Journal of Neuroradiology. 2021;42(1):2-11.
72. Bonkhoff, AK, Grefkes, C. Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence, Brain, 2022;145(2):457-75
73. Shi M-G, Feng X-M, Zhi H-Y, Hou L, Feng D-F. Machine learning-based radiomics in neurodegenerative and cerebrovascular disease. MedComm. 2024;5(11):e778.
74. Choi, H, Seo, S, Kim, JH, Cho, H, Kang, SH, Ye, B. PET/MR imaging in the diagnosis of cerebral small vessel disease. Annals of Clinical and Translational Neurology, 2018;5(6):747-56.
75. Karel MFA, Roosen MGCH, Tullemans BME, Zhang CE, Staals J, Cosemans JMEM, et al. Characterization of cerebral small vessel disease by neutrophil and platelet activation markers using artificial intelligence. Journal of Neuroimmunology. 2022;367:577863.
76. Debette S, Schilling S, Duperron M-G, Larsson SC, Markus HS. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis. JAMA Neurology. 2019;76(1):81-94.
77. Ter Telgte, A., van Leijsen, E. M., Wiegertjes, K., Klijn, C. J., & de Leeuw, F. E. (2018). Cerebral small vessel disease: From a focal to a global perspective. Nature Reviews Neurology, 14(7), 387-398.